4.3 Article

miR-31 affects colorectal cancer cells by inhibiting autophagy in cancer-associated fibroblasts

Journal

ONCOTARGET
Volume 7, Issue 48, Pages 79603-79614

Publisher

IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.12873

Keywords

miR-31; colorectal cancer; CAFs; autophagy; biological behaviors

Funding

  1. National Natural Science Foundation of China [81672970, 81301933, 81472917, 81572345]
  2. Health Research Projects in Jiangsu Province [H201313]
  3. Suzhou Technology Bureau [SYSD2013090, SYS201552, SYSD2015034]
  4. Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)
  5. Suzhou Science and Education health youth projects [kjxw2015050]
  6. Taicang Municipal Science and Technology Bureau of Basic Research Program [TC2015YYYL01]
  7. focus of clinical disease treatment technology special funds of Suzhou city [LCZX201505]
  8. Soochow university

Ask authors/readers for more resources

Autophagy is a double-edged sword in tumor development. Recent studies have found that miRNAs have an inhibitory effect on the regulation of autophagy. It has been reported that miR-31 plays an important role in the development of colorectal cancer. However, what role miR-31 plays in colorectal cancer-associated fibroblasts (CAFs) has not been determined. In this study, we confirmed that the expression of miR-31 in CAFs was higher than in normal colorectal fibroblasts (NFs). We also found that treatment of CAFs with miR-31 mimic inhibited the expression of the autophagy-related genes Beclin-1, ATG, DRAM and LC3. In addition, we found up-regulation of miR-31 significantly affected colorectal cancer cell behaviors, including proliferation, invasion and apoptosis. Also, up-regulation of miR-31 in CAF could increase the radiosensitivity of colorectal cancer cells co-cultured with CAF. In summary, miR-31 can inhibit autophagy in colorectal CAFs, affect colorectal cancer development, and increase the radiosensitivity of colorectal cancer cells co-cultured with CAF. We hypothesize that miR-31 may become a new target of treatments for colorectal cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available